Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

Non-GAAP EPS Increased 22 Percent

CAMBRIDGE, Mass., April 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported results for the first quarter of 2008, which featured excellent revenue growth, continued operating leverage, a significant increase in non-GAAP profit, and strong progress across the company.

First-Quarter Highlights

-- Total revenue for the quarter grew 25 percent to $1.1 billion from

$883.2 million in same period a year ago. This increase was driven by

growth across all product lines, led by strong growth in sales of

treatments for lysosomal storage disorders and renal disease.

Genzyme's top line now includes sales of Aldurazyme(R) (laronidase),

which previously were recorded as joint venture revenue.

-- GAAP net income in the first quarter was $145.3 million, or $0.52 per

diluted share, compared with $158.2 million, or $0.57 per diluted

share. GAAP net income in this year's first quarter reflects an after-

tax charge of $56.5 million for the premium related to Genzyme's

strategic investment in Isis Pharmaceuticals Inc.

-- Non-GAAP net income increased 24 percent to $260.9 million, compared

with $210.7 million in the first quarter a year earlier. Non-GAAP

earnings increased 22 percent to $0.95 per diluted share from $0.78 per

diluted share in the first quarter last year.

-- Non-GAAP operating expenses decreased as a percentage of revenue,

reflecting global operating leverage.

-- Genzyme continued to generate significant cash from operations and to

reinvest in the future of the company. In the first quar
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 More than ... and about 1 in 3 seniors will die with ... ). These jaw-dropping figures have shocked many Americans into ... hopefully, help prevent these tragic age-related cognitive disorders. Jonathan ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how ... latent viruses is the Epstein Barr Virus (EBV), and one ... is a chronic inflammatory disease that destroys the body’s joints. ... patients have high concentrations of EBV DNA in their bodies ...
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... , SAN DIEGO, July 30 Cardium ... to develop a DNA-based orthobiologics product portfolio based on research ... focus on non-union bone fractures for medically-compromised patients, and spinal ... a rapidly growing segment of the orthopedics market and represents ...
... , NEW YORK, July 30 Stemline Therapeutics, ... of oncology compounds directed to cancer stem cell targets, today ... invited to present at the New Frontiers in Cancer Drug ... Development Week in Boston, MA. Dr. Bergstein,s presentation, entitled ...
... July 30 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc.,(OTC Bulletin ... developer and,producer of prescriptions drugs and licensed national ... China, today reported it received notice,of patent pending ... People,s,Republic of China for its innovative patent application ...
Cached Biology Technology:Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 2Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 3Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 4Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 5Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 6Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 7Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 8Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 9Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 10Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference 2Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets 2Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets 3
(Date:4/17/2014)... are implicated in many serious conditions such as heart ... target for drug therapies. Unfortunately, there is still much ... research provides fresh and unexpected insight into the structure ... - β-subunit molecules - which are responsible for ,fine-tuning, ... in the most recent edition of the Journal ...
(Date:4/17/2014)... is the process whereby the genetic information of ... as proteins, which have numerous different functions in ... important intermediary during gene expression, by relating the ... involved in manufacturing proteins. , By examining ... present in an organism at a given time, ...
(Date:4/17/2014)... by the Australian National University (ANU), have developed ... deep-sea temperature variability over the past 5.3 million ... the climate surrounding ice ages over the past ... relationship between carbon dioxide levels, global temperatures and ... of Southampton (UoS) and the National Oceanography Centre ...
Breaking Biology News(10 mins):Structure of sodium channels different than previously believed 2Rapid and accurate mRNA detection in plant tissues 2Ancient sea-levels give new clues on ice ages 2
... to caution about the many things that could go ... contain a Southeast Asian outbreak of avian influenza in ... vaccine. , Using a computer model to simulate an ... have shown how a combination of strategies, including targeted ...
... and not the last ice age are the likely culprits ... American great mammals such as mammoths, mastodons and saber-toothed tigers, ... first arrival of humans or the warm-up of the American ... responsible for the demise of prehistoric sloths has puzzled scientists ...
... Canada in 2004 emitted about as much carbon monoxide ... during the same time period, according to new research ... fires also increased atmospheric concentrations of ground-level ozone across ... which indicates the extent to which wildfires contribute to ...
Cached Biology News:Preventing a pandemic: Study suggests strategies for containing a flu outbreak 2Preventing a pandemic: Study suggests strategies for containing a flu outbreak 3Study shows big game hunters, not climate change, killed off sloths 2Study shows big game hunters, not climate change, killed off sloths 3NCAR analysis shows widespread pollution from 2004 wildfires 2
... in a regulated environment, Pipette Tracker ... software that automates gravimetric pipette calibration ... that meets todays regulatory compliance requirements. ... solution that includes a full security ...
... AAIPharmas Routine Testing Laboratory (RTL) ... developed over 25 years. ,,Microbial method ... used to monitor the conditions of ... quality for manufactured products,,We offer a ...
... Research Scale (gram quantities of IgY) , ... Prepare your Antigen), we segregate the appropriate number ... After 3 such eggs are collected (usually over ... injection series. This involves a total of four ...
... cDNA Library Panels were designed for full-length ... of PCRs to identify the desired cDNA ... in a 96-well "Master Plate," where each ... Having identified the positive well(s) by gel ...
Biology Products: